This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
4 Stocks to Watch in the Growing Nanotechnology Market
by Kaustav Ghosh
Watch out for names like Onto Innovation (ONTO), DuPont de Nemours (DD), Thermo Fisher Scientific (TMO) and International Business Machines (IBM) as the nanotechnology market continues to grow.
The Zacks Analyst Blog Highlights: JPMorgan, PayPal, Thermo Fisher Scientific, PepsiCo, McDonald's and Canadian National Railway
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, PayPal, Thermo Fisher Scientific, PepsiCo, McDonald's and Canadian National Railway
Top Analyst Reports for JPMorgan, PayPal & Thermo Fisher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), PayPal (PYPL), and Thermo Fisher Scientific (TMO).
3 Medical Diagnostics Stocks in Focus on Long-Term Potential
by Riya Anand
MedTech testing stocks like Quest Diagnostics Incorporated (DGX), Thermo Fisher Scientific, Inc. (TMO) and Laboratory Corporation of America Holdings (LH) are likely to survive post-pandemic.
Thermo Fisher Scientific (TMO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed at $445.33 in the latest trading session, marking a -0.86% move from the prior day.
Moderna (MRNA) Files for Full Approval of COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) seeks full approval for its COVID-19 vaccine, mRNA-1273, in adults with initiation of rolling submission of a BLA. The company also boosts manufacturing capacity for the vaccine.
LabCorp (LH) New Study Looks at COVID-19 Antibody Longevity
by Zacks Equity Research
LabCorp (LH) claims this to be the largest known COVID-related study in terms of specimen volume.
Thermo Fisher's (TMO) New Alliance Boosts Electron Microscopy
by Zacks Equity Research
This instrument by Thermo Fisher (TMO) is set to play a vital role in developing advanced solar cells, transport alloys, battery materials, low-energy electronics, catalysts and biodegradable polymers.
Thermo Fisher (TMO) to Boost Cell Therapies With UCSF Deal
by Zacks Equity Research
Thermo Fisher's (TMO) collaboration with UCSF will enable end-to-end solution to accelerate cell therapy development and manufacturing with new facility.
The Zacks Analyst Blog Highlights: UnitedHealth, PayPal, NextEra Energy, Thermo Fisher Scientific and Anheuser-Busch InBev
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, PayPal, NextEra Energy, Thermo Fisher Scientific and Anheuser-Busch InBev
Top Stock Reports for UnitedHealth, PayPal & NextEra
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), PayPal (PYPL), and NextEra (NEE).
Healthcare ETFs on Radar As Q1 Earnings Unfold
by Sweta Killa
Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns.
Medical Products' Apr 29 Earnings Roster: TMO, BAX & More
by Trina Mukherjee
The Medical Product companies' first-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.
Is a Surprise Coming for Thermo Fisher (TMO) This Earnings Season?
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results are likely to reflect strong performance at Diagnostics segment.
Thermo Fisher (TMO) to Report Q1 Earnings: WIll It Beat?
by Zacks Equity Research
Fewer hospital visits on growing new cases might have once again impacted the level of routine diagnostics testing activity for Thermo Fisher (TMO) in Q1.
Baxter (BAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.
Thermo Fisher Scientific (TMO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stryker (SYK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) first-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Thermo Fisher (TMO) to Expand in Pharma Service With PPD Buyout
by Zacks Equity Research
Thermo Fisher's (TMO) $17.4-billion acquisition deal will offer the company meaningful cost and revenue synergies.
MedTech M&A Scaling New Heights in 2021 on Rising Investor Wealth
by Urmimala Biswas
While smaller tuck-in acquisitions dominated the M&A space throughout 2020, 2021 is seeing a number of colossal deals.
5 ETFs to Make the Most of Thermo Fisher Deal to Buy PPD
by Sweta Killa
Thermo Fisher Scientific (TMO) has agreed to buy the healthcare testing company PPD Inc. (PPD) for $17.4 billion in cash.
Company News for Apr 16, 2021
by Zacks Equity Research
Companies in the news are: BLK, PEP, DELL, TMO